Abstract 988P
Background
Liver cancer is a leading cause of cancer-related mortality worldwide. There is a literature gap regarding its burden in the Middle East and North Africa (MENA) region. Therefore, we aimed to investigate the epidemiological trends of primary liver cancer in the MENA region from 1990 to 2019.
Methods
The Global Burden of Disease database was used to extract the age-standardized rates per 100,000 population for prevalence (ASRP), incidence (ASRI), and years lived with disability (YLDs) of primary liver cancer in the MENA region between 1990 and 2019. Data were analyzed to identify regional distribution patterns across different countries and demographic groups using Wilcoxon signed-rank test.
Results
ASRP for liver cancer in the MENA region was significantly higher in 2019 compared to 1990 (median of 4.34 and 5.38 in 1990 and 2019, respectively; P= 0.002). The major causes of primary liver cancer were hepatitis C virus, followed by hepatitis B virus, nonalcoholic steatohepatitis, and alcohol use. In 2019, the highest ASRP was observed in Qatar (24.894; 95% confidence interval (CI): 18.34-33.24) and Egypt (22.575; 95% CI: 16.20-30.90), while Morocco had the lowest one (2.21; 95% CI: 1.68-2.70). On the other hand, no significant increase was observed from 1990 to 2019 for the ASRI (median of 4.26 and 4.49 in 1990 and 2019, respectively, P = 0.498) and YLDs (median of 0.96 and 1.04 in 1990 and 2019, respectively, P = 0.079).
Conclusions
The prevalence of liver cancer shows a rising trend in the MENA region from 1990 to 2019. Adopting regional programs to address the major risk factors should be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18